GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zydus Lifesciences Ltd (NSE:ZYDUSLIFE) » Definitions » EV-to-EBIT

Zydus Lifesciences (NSE:ZYDUSLIFE) EV-to-EBIT : 21.53 (As of May. 28, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Zydus Lifesciences EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Zydus Lifesciences's Enterprise Value is ₹1,053,042 Mil. Zydus Lifesciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was ₹48,901 Mil. Therefore, Zydus Lifesciences's EV-to-EBIT for today is 21.53.

The historical rank and industry rank for Zydus Lifesciences's EV-to-EBIT or its related term are showing as below:

NSE:ZYDUSLIFE' s EV-to-EBIT Range Over the Past 10 Years
Min: 9.08   Med: 19.33   Max: 40.52
Current: 21.53

During the past 13 years, the highest EV-to-EBIT of Zydus Lifesciences was 40.52. The lowest was 9.08. And the median was 19.33.

NSE:ZYDUSLIFE's EV-to-EBIT is ranked worse than
60.63% of 668 companies
in the Drug Manufacturers industry
Industry Median: 16.995 vs NSE:ZYDUSLIFE: 21.53

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Zydus Lifesciences's Enterprise Value for the quarter that ended in Mar. 2024 was ₹1,024,240 Mil. Zydus Lifesciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was ₹48,901 Mil. Zydus Lifesciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 4.77%.


Zydus Lifesciences EV-to-EBIT Historical Data

The historical data trend for Zydus Lifesciences's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zydus Lifesciences EV-to-EBIT Chart

Zydus Lifesciences Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 19.50 19.78 13.04 19.09 20.90

Zydus Lifesciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.09 17.60 16.98 18.25 20.90

Competitive Comparison of Zydus Lifesciences's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Zydus Lifesciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zydus Lifesciences's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Zydus Lifesciences's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Zydus Lifesciences's EV-to-EBIT falls into.



Zydus Lifesciences EV-to-EBIT Calculation

Zydus Lifesciences's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=1053041.990/48901
=21.53

Zydus Lifesciences's current Enterprise Value is ₹1,053,042 Mil.
Zydus Lifesciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹48,901 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Zydus Lifesciences  (NSE:ZYDUSLIFE) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Zydus Lifesciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 ) =EBIT / Enterprise Value (Q: Mar. 2024 )
=48901/1024239.7905
=4.77 %

Zydus Lifesciences's Enterprise Value for the quarter that ended in Mar. 2024 was ₹1,024,240 Mil.
Zydus Lifesciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹48,901 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Zydus Lifesciences EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Zydus Lifesciences's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Zydus Lifesciences (NSE:ZYDUSLIFE) Business Description

Traded in Other Exchanges
Address
Scheme No. 63, Sarkhej-Gandhinagar Highway, Zydus Corporate Park, Survey No. 536, Near Vaishnodevi Circle, Khoraj (Gandhinagar), Ahmedabad, GJ, IND, 382481
Zydus Lifesciences Ltd is a specialty and generic drug manufacturing company. The product portfolio of the group includes Active Pharmaceutical Ingredients, human formulations, Health and wellness, and Animal health and veterinary products. Its product brands include Aten, Falcigo, Nucoxia, Levoday, Metscore and Arzep among others. It has two segments Pharmaceuticals and Consumer Products. It generates majority of its revenue from the Pharmaceutical segment.

Zydus Lifesciences (NSE:ZYDUSLIFE) Headlines

No Headlines